Search Within

Saad Zafar Usmani

Formats
  1. Meeting Abstract (223)
  2. Journal Article (82)
  3. Review (16)
  4. Research Letter (11)
  5. Correspondence (5)
  6. Editorial (4)
  7. Guidelines (3)
  8. Book Section (1)
Groups
  1. Hematologic Malignancies, Division of (171)
  2. Department of Medicine (168)
  3. Center for Hematologic Malignancies (161)
  4. Graduate Medical Education (151)
  5. Myeloma (149)
  6. GME, Medicine (142)

More Groups

People
  1. Alexander Lesokhin (129)
  2. Kylee Maclachlan (127)
  3. Sham Mailankody (113)
  4. Urvi Shah (110)
  5. Carlyn Rose Tan (105)
  6. Neha Korde (103)

More People

Years
  1. 2025 (42)
  2. 2024 (97)
  3. 2023 (123)
  4. 2022 (83)
Publications
  1. Blood (110)
  2. Clinical Lymphoma, Myeloma and Leukemia (81)
  3. Journal of Clinical Oncology (32)
  4. Blood Cancer Journal (16)
  5. Blood Advances (15)
  6. British Journal of Haematology (8)

More Publications

Publishers
  1. American Society of Hematology (125)
  2. Elsevier Inc. (94)
  3. American Society of Clinical Oncology (32)
  4. Nature Publishing Group (24)
  5. Elsevier Science, Inc. (10)
  6. John Wiley & Sons (9)

More Publishers

Results (345)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mutagenic impact and evolutionary influence of chemoradiotherapy in hematologic malignancies
    Journal Article

    Diamond, B.; Chahar, D.; Jain, M. D.; Poos, A. M.; Durante, M. A.; Ziccheddu, B.; Kaddoura, M.; Papadimitriou, M.; Maclachlan, K. H.; Jelinek, T.; more...
    Blood Cancer Discovery (2025)

    Fulltext@MSK | Save
  • Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma
    Journal Article

    Garces, J. J.; Diamond, B.; Sevcikova, T.; Nenarokov, S.; Bilek, D.; Radova, E.; Venglar, O.; Kapustova, V.; Firestone, R.; Maclachlan, K.; more...
    HemaSphere (2025)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone in TE NDMM: PERSEUS/GRIFFIN pooled analysis of patients ≥65 years
    Meeting Abstract

    Sonneveld, P.; Rodríguez-Otero, P.; Voorhees, P. M.; Boccadoro, M.; Laubach, J.; Einsele, H.; Sborov, D.; Dimopoulos, M. A.; Broijl, A.; Mina, R.; more...
    British Journal of Haematology (2025)

    Fulltext@MSK | Save
  • Belantamab mafodotin with standard care in transplant-ineligible newly diagnosed multiple myeloma: DREAMM-9 phase I study
    Meeting Abstract

    Khalaf, Z.; Usmani, S. Z.; Mielnik, M.; Garg, M.; Sandhu, I.; Abdallah, A. O.; Koh, Y.; Oriol, A.; Quach, H.; Weisel, K. C.; more...
    British Journal of Haematology (2025)

    Fulltext@MSK | Save
  • Daratumumab + bortezomib/lenalidomide/dexamethasone versus VRd in transplant-ineligible/ transplant-deferred NDMM: MRD analysis of the CEPHEUS study
    Meeting Abstract

    Basu, S.; Zweegman, S.; Facon, T.; Hungria, V.; Bahlis, N. J.; Venner, C. P.; Braunstein, M.; Rowe, M.; Carson, R.; Usmani, S.
    British Journal of Haematology (2025)

    Fulltext@MSK | Save
  • Daratumumab + bortezomib/lenalidomide/dexamethasone in transplant ineligible/ transplant deferred newly diagnosed MM: Phase 3 CEPHEUS results
    Meeting Abstract

    Basu, S.; Usmani, S.; Facon, T.; Hungria, V.; Bahlis, N.; Venner, C.; Braunstein, M.; Rowe, M.; Carson, R.; Zweegman, S.
    British Journal of Haematology (2025)

    Fulltext@MSK | Save
  • Temporal genomic dynamics shape clinical trajectory in multiple myeloma
    Journal Article

    Maura, F.; Kaddoura, M.; Poos, A. M.; Baughn, L. B.; Ziccheddu, B.; Bärtsch, M. A.; Cirrincione, A.; Maclachlan, K.; Chojnacka, M.; Diamond, B.; more...
    Nature Genetics (2025)

    Fulltext@MSK | Save
  • Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma
    Journal Article

    Adegbite, B.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • International Myeloma Society/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma
    Guidelines

    Avet-Loiseau, H.; Davies, F. E.; Samur, M. K.; Corre, J.; D'Agostino, M.; Kaiser, M. F.; Raab, M. S.; Weinhold, N.; Gutierrez, N. C.; Paiva, B.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Ibrutinib in combination with lenalidomide revlimid/dexamethasone in relapsed/refractory multiple myeloma (AFT-15)
    Journal Article

    Efebera, Y.; Suman, V.; Dinner, S.; O’Donnell, T.; Rosko, A.; McKay, J.; Barth, P.; Hagen, P.; Usmani, S.; Richardson, P.; more...
    Cancers (2025)

    Fulltext@MSK | Save